Ranexa + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cardiomyopathy
Conditions
Cardiomyopathy, Chest Pain, Dyspnea
Trial Timeline
Apr 1, 2011 → Apr 1, 2014
NCT ID
NCT01345188About Ranexa + Placebo
Ranexa + Placebo is a approved stage product being developed by Gilead Sciences for Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01345188. Target conditions include Cardiomyopathy, Chest Pain, Dyspnea.
What happened to similar drugs?
6 of 20 similar drugs in Cardiomyopathy were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01345188 | Approved | Completed |
Competing Products
20 competing products in Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib + Placebo | AMO Pharma | Phase 2 | 32 |
| Mavacamten | LianBio | Phase 1 | 19 |
| Mavacamten + Placebo | LianBio | Phase 3 | 30 |
| CT-G20 + Placebo | Celltrion | Phase 1 | 21 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 43 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 21 |
| AZD4063 | AstraZeneca | Phase 1 | 36 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| candesartan | AstraZeneca | Phase 2 | 31 |
| LCZ696 + Placebo | Novartis | Phase 2 | 35 |
| Darbepoetin alfa | Amgen | Pre-clinical | 26 |
| Eleclazine + Placebo | Gilead Sciences | Phase 2/3 | 30 |
| Ranolazine | Gilead Sciences | Approved | 43 |
| Ranolazine | Gilead Sciences | Pre-clinical | 18 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 39 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |